Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma

Hematological Oncology

Volumn 32, Issue 4, 2014, Pages 187-191

  Garciaz, Sylvain ^a   Coso, Diane ^a   Peyrade, Frederic ^b   Fürst, Sabine ^a   Duran, Ségolène ^a   Chetaille, Bruno ^a   Brenot Rossi, Isabelle ^a   Devillier, Raynier ^a   Granata, Angela ^a   Blaise, Didier ^a   Bouabdallah, Réda ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Allogeneic transplantation; Brentuximab vedotin; Hodgkin lymphoma

Indexed keywords

BRENTUXIMAB VEDOTIN; ANTIBODY CONJUGATE; CAC10-VCMMAE; CD30 ANTIGEN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CLINICAL ARTICLE; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; TREATMENT RESPONSE; ALLOTRANSPLANTATION; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DISEASE FREE SURVIVAL; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; METABOLISM; MIDDLE AGED; RECURRENT DISEASE; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIGENS, CD30; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; LYMPHOCYTES; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84914147333     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2119     Document Type: Article

References (15)

1. Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant 1997; 20(1): 21-26.
2. Morschhauser F, Brice P, Ferme C, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008; 26(36): 5980-5987.
3. Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010; 115(18): 3671-3677.
4. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363(19): 1812-1821.
5. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30(18): 2183-2189.
6. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25(5): 579-586.
7. Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007; 18(6): 1071-1079.
8. Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin (SGN-35) in patients with relapsed/refractory CD30-positive hematologic malignancies without prior high-dose chemotherapy and stem cell transplantation [abstract 2743]. Blood (ASH Annual Meeting Abstracts). 2012;120).
9. Forero-Torres A, Fanale M, Advani R, et al. Brentuximab vedotin in transplant-naive patients with relapsed or refractory Hodgkin lymphoma: analysis of two phase I studies. Oncologist 2012; 17: 1073-1080.
10. Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a named patient programme at a single UK Centre. Haematologica 2012; 98(4): 611-614.
11. Smith S, Chen R, Gopal A, et al. Long-term follow-up results of an ongoing pivotal study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (HL) [abstract 1109]. Haematol Hematol J 2012; 97(suppl 1).
12. Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012; 119(26): 6379-6381.
13. Devillier R, Coso D, Castagna L, et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Haematologica 2012; 97(7): 1073-1079.
14. Gopal AK, Ramchandren R, O'Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012; 120(3): 560-568.
15. Theurich S, Malcher J, Wennhold K, et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol 2013; 31(5): e59-e63.